Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00383526 | Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly | PHASE3 | COMPLETED | 3,707 | — | — | Sep 1, 2006 | Sep 1, 2009 | Jan 14, 2014 | 4 | Belgium, France +2 |
| NCT00296829 | Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly | PHASE2 | COMPLETED | 1,080 | — | — | Jan 1, 2006 | Feb 1, 2007 | Jan 14, 2014 | 11 | Australia, New Zealand |
| Arm | Type | Description |
|---|---|---|
| Study Group 1 | EXPERIMENTAL | - |
| Study Group 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Inactivated, split-virion influenza vaccine | BIOLOGICAL | Vaccine |
Inclusion Criteria: * Aged over 60 years on the day of inclusion. * Informed Consent Form signed. * Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: * Systemic hypersensitivity to egg proteins, chick proteins, or any of the vaccine components, in pa...